ArticleRadiation oncology (London, England)2026
Differential biological effects of scattered versus scanned clinical proton beams on Ewing sarcoma models.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundProton therapy (PT), first delivered passively using the Double Scattering (DS) technique, has shifted to active delivery through the Pencil Beam technique (PBS). However, the biological effectiveness of DS versus PBS proton beams on cancer cells, remain largely unknown. Given that PBS-PT is now commonly used to treat young patients with Ewing sarcoma, this point is of major importance in clinical practice and raises the question of the same effectiveness of both proton modalities on tumor control.
methodsThis study aims to compare the biological effects of clinical PBS vs. DS proton beams on various Ewing sarcoma cell lines. For this, we used a clinical Proteus 235 isochronous cyclotron capable of delivering both PBS and DS treatment modalities. Three different cancerous Ewing cell models were irradiated either in the plateau or in mid Spread-Out Bragg Peak (SOBP). We performed cell survival assays (2D monolayers and 3D spheroids), along with Reactive Oxygen Species (ROS) production (CellRox deep red assay) and quantification of 53BP1 foci 1 h and 18 h post-irradiation by immunofluorescence.
resultsNo significant differences were observed in cell survival (either in 2D or in 3D) at the plateau or mid-SOBP between the two proton treatment modalities. However, higher ROS production and a greater number of residual 53BP1 foci were observed in PBS compared to DS technique.
conclusionsBoth PBS and DS proton irradiation modalities exhibit the same in vitro biological effectiveness on Ewing sarcoma models. However, the question of the possible influence of the ROS/53BP1 increase on the onset of side effects or late toxicities when using the PBS irradiation technique, may arise.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.